Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Comparative, Multi-Centre, Phase II Prospective Trial to Assess the Efficacy of Quetiapine Fumarate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) in SSRI-Resistant Major Depressive Disorder.

NCT00733668 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00733668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00733668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Comparative, Multi-Centre, Phase II Prospective Trial to Assess the Efficacy of Quetiapine Fumarate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) in SSRI-Resistant Major Depressive Disorder.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
November 30, 2007
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder